Hemispherx (HEB) Surges on News Mgmt to Hold Conference Call Updating Influenza Research Initiatives
HEB Hot Sheet
Financial Fact:General and administrative: 1.87M
Today's EPS Names:
VSNT, CIM, KH, More
Shares of the momentous swine flu play, Hemispherx BioPharma (AMEX: HEB), have surged today following reports earlier that the company will issue an update on its Influenza research initiatives via a teleconference on Wednesday, July 22 at 10am ET.
According to the press release issued by Hemispherx this morning, initiatives which will be discussed include experimental programs planned or underway in Pacific Rim countries, Australia, South America and the United States. Also, investigational products and protocols to be discussed will include Hemispherx's Ampligen(r) (poly I: poly C12U), Alferon N (a natural cocktail of alpha 2 type interferons, FDA approved for treatment of refractory HPV) and Alferon LDO, an experimental formulation of Alferon-N for oral delivery.
Hemispherx's CEO and Medical Director, Bill Carter, is expected to participate in the teleconference.
Hemispherx shares are currently 15% higher on the news, most recently trading at $2.43. Notably, the stock is seeing heavier-than-normal volume today, already trading more than 5 million times, which compares to the stock's average daily volume of about 7 million shares.
According to the press release issued by Hemispherx this morning, initiatives which will be discussed include experimental programs planned or underway in Pacific Rim countries, Australia, South America and the United States. Also, investigational products and protocols to be discussed will include Hemispherx's Ampligen(r) (poly I: poly C12U), Alferon N (a natural cocktail of alpha 2 type interferons, FDA approved for treatment of refractory HPV) and Alferon LDO, an experimental formulation of Alferon-N for oral delivery.
Hemispherx's CEO and Medical Director, Bill Carter, is expected to participate in the teleconference.
Hemispherx shares are currently 15% higher on the news, most recently trading at $2.43. Notably, the stock is seeing heavier-than-normal volume today, already trading more than 5 million times, which compares to the stock's average daily volume of about 7 million shares.
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Signet Jewelers (SIG) Tops Q1 EPS by 5c; Guides Q2 Below the Street
- Bazaarvoice (BV) Agrees to Buy PowerReviews; Offers Prelim. Q1 Results, Guides Q2, FY13
Create E-mail Alert Related Categories
Corporate News, Guidance, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
